Company news

CARsgen Therapeutics Holdings Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026

November 5, 2026

Voluntary announcement - abstracts of CT1190B and CT071 published at ASH 2026 annual meeting

November 4, 2026

Voluntary announcement - research results of satri-cel at the ESMO congress 2026

October 25, 2026

Voluntary announcement - first patient dose of CT0596 in china phase i registrational trial

October 12, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 7, 2026

List of directors and their roles and functions

September 30, 2026

Resignation of non-executive director and non-compliance with rule 3.21 of the listing rules

September 30, 2026

Voluntary announcement - first patient dose of CT1190B in china phase i registrational trial

September 28, 2026

Interim report 2026

September 15, 2026

CARsgen Therapeutics Announces 2026 Interim Results

August 18, 2026

CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors

June 22, 2026

CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026

June 14, 2026

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting

May 31, 2026

CARsgen Therapeutics Announces 2025 Annual Results

March 6, 2026

CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in Jinshan, Shanghai

February 12, 2026

Dispatch Bio and CARsgen Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

January 12, 2026

CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

January 12, 2026

CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596

December 28, 2025

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

December 7, 2025

CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue

December 7, 2025

CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B

November 3, 2025

CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025

October 19, 2025

Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia

October 19, 2025

CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology

October 7, 2025

CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025

September 17, 2025

CARsgen Therapeutics Announces 2025 Interim Results

August 14, 2025

CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO

July 12, 2025

CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China's NMPA

June 25, 2025

CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting

June 1, 2025

CARsgen's Satri-cel Granted Priority Review by the NMPA

May 28, 2025

CARsgen's Satri-cel Abstract Available on ASCO Website

May 21, 2025

CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy

May 10, 2025

CARsgen Announced 2024 Annual Results

March 18, 2025

CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA

March 2, 2025

CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease

February 27, 2025

CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China

February 25, 2025

Decks

The 5 newest of 17 decks. Every deck is listed under its year.